In the face of the COVID-19 ravaging the world, since the day of its birth, Sharetry has taken the integration of R&D, registration, manufacture, sales, and market resources of medical devices and in vitro diagnostic devices as our inescapable responsibility and mission. Besides, Sharetry is also a high-tech enterprise that can confidently cope with unknown challenges and opportunities.
In order to realize the change and value brought about by science, technology, and innovation, we have established multiple R & D centers and wholly-owned subsidiaries in China and other countries in Asia in 4 years, together with nearly 200 partners, under the leadership of more than 100 outstanding young scientists.Based on existing laws, regulations, and systems, we have built innovative, sustainable, and challenging professional in vitro diagnostic devices customized Contract Manufacture platform (CMO), Contract Development Manufacture (CDMO), and Contract Regulatory Affairs platform (CRAO).
The one-stop 3C platform provides fair, high-quality, and efficient solutions and has served over 100 customers around the world, covering immunofluorescence, biochemistry, specific protein, coagulation, COVID-19, pet test, drug test, rapid test, and test at home.
We have efficiently provided more than 300 high-quality products and Sharetry has grown into the world's top supplier of one-stop 3C solutions for in vitro diagnostic devices. While providing high-quality technology and services, we have developed more than 100 autoantibody quantitative assay kits, 55 allergen assay kits, 6 thrombus assay kits, and 14 POCT assay kits based on chemiluminescence platforms. We have obtained 97 registration certificates for Class II medical devices from NMPA and over 400 products have been CE marked. Sharetry has become a leading enterprise in China and even Asia in the field of autoantibody and allergy detection.
In order to timely cope with the challenges and opportunities, we have independently developed more than 20 critical raw materials for IVD reagents (mainly recombinant autoimmune antigens and allergen components), which have been widely used in the development of assay kits. We attach great importance to intellectual property rights and have obtained 28 national patents, 8 software copyrights, 15 utility model patents, 1 invention, patent, and 4 appearance patents. In addition, 31 patents (including 22 invention patents) are under review.
Taking technological innovation as our own responsibility, and "high starting point, strict standards" as our development policy, we always stick to innovation, adhere to R & D of technology, with the ideal of "becoming the world's leading in-vitro diagnostic enterprise", export high-quality services and diagnostic products to the world, and take care of the patient’s health.